Replies to post #103967 on Biotech Values

[DewDiligence]

GSK/GenMab advance Ofatumumab MS program to phase-2b using subcutaneous formulation, pending feedback from regulatory authorities:

http://finance.yahoo.com/news/GlaxoSmithKline-and-Genmab-pz-2645108315.html?x=0&.v=1

No further development of Ofatumuab will be undertaken in any indication using the IV formulation. Also, the Ofatumuab program in RA is “under review” by GSK/Genmab, which sounds like it’s going to be canned.